Silk Road Medical Inc
SILKHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | |
|---|---|---|---|---|---|---|
| Revenue | $177.1M | $138.6M | $101.5M | $75.2M | $63.4M | $34.6M |
| Operating income | −$59.3M | −$52.0M | −$47.5M | −$42.9M | −$28.1M | −$21.4M |
| Net income | −$55.7M | −$55.0M | −$49.8M | −$47.4M | −$52.4M | −$37.6M |
| Total assets | $265.3M | $269.7M | $156.6M | $179.3M | $137.4M | $42.7M |
| Total liabilities | $114.2M | $105.8M | $77.4M | $71.8M | $65.5M | $72.1M |
| Equity | $151.2M | $163.9M | $79.2M | $107.5M | $71.9M | −$134.6M |
| EPS (diluted) | $-1.44 | $-1.54 | $-1.44 | $-1.44 | — | — |
| Shares out. | 38.5M | 35.0M | 34.4M | 31.4M | 31.3M | 1.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −33.5%
- Net margin
- −31.5%
- Return on equity
- −36.9%
- Return on assets
- −21.0%
- Return on capital (ROCE)
- −25.2%
- Liabilities / assets
- 43.0%
- Debt / equity
- 0.76×
- Book value / share
- $3.93
- Revenue growth (YoY)
- 27.8%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 0.19distress
- Accruals / assets
- −8.9%clean
- Beneish M-Score
- -1.84normal
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Debt acceleration / triggering event · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsSep 17, 2024
- Other material eventSep 13, 2024
- Shareholder voteSep 6, 2024
- Other material eventAug 9, 2024
- Results of operationsAug 7, 2024
- Shareholder voteJun 20, 2024
- Entered a material agreement · Other material eventJun 18, 2024
- Results of operationsApr 30, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.